News Sentiment

ASND sentiment intelligence

Ascendis Pharma AS news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 64 Constructive news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 230.83 Week of 19 Jun 2026
Weighted tone 64/100

Constructive news tone

Market reaction News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update

77/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+5.9% over one week, -6.6% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating

Market Reaction

News confirmed by price

74/100 confidence

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update 77/100 classification
One-week reaction 5.9% Price confirming higher
Trend fit Trend inactive -6.6% over four weeks
Fair value 47.2% Materially above fair value
Sentiment-trend disagreement Positive but stretched

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 32
Neutral 24
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Investing.com 10
Market source 10
Quiver Quantitative 4
GlobeNewswire 3
simplywall.st 3
Moomoo 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 19
Analyst action 8
Regulatory and legal 3
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
MLQ.ai Direct company coverage

Ascendis Pharma A/S

The Ascendis Pharma A/S (ASND) analyst forecast page on MLQ.ai provides an overview of its market data, including market capitalization, volume, and various research categories like earnings, financials, and analyst ratings. The page indicates a current consensus of 0 buy, 0 hold

Tone
Neutral 50/100
Event
Earnings
Published
02 Jun 2026 23:10
Source
MLQ.ai
Stock Titan Direct company coverage

Ascendis Pharma (ASND) CFO acquires 100 Ordinary Shares in open-market buy

Ascendis Pharma A/S's EVP & Chief Financial Officer, Scott Thomas Smith, purchased 100 Ordinary Shares in an open-market transaction on June 2, 2026, at $219.00 per share. This transaction increases his direct holdings to 4,367 Ordinary Shares. The insider trade shows a positive

Tone
Positive 68/100
Event
Market update
Published
02 Jun 2026 20:24
Source
Stock Titan
Stock Traders Daily Direct company coverage

(ASND) Movement as an Input in Quant Signal Sets

This article provides an AI-generated analysis for Ascendis Pharma A/s (NASDAQ: ASND), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-ti

Tone
Negative 40/100
Event
Guidance
Published
02 Jun 2026 18:44
Source
Stock Traders Daily
Stock Titan Direct company coverage

Ascendis Pharma (ASND) director adds 500 shares in open-market buys

Ascendis Pharma A/S director Jean Jacques Bienaime recently purchased 500 Ordinary Shares through three open-market transactions on May 29, 2026, with prices ranging from $222.30 to $223.76 per share. Following these buys, Bienaime directly holds 600 Ordinary Shares of Ascendis P

Tone
Positive 74/100
Event
Market update
Published
01 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Ascendis Pharma (NASDAQ: ASND) CFO details shares, RSUs and warrant stakes

Ascendis Pharma A/S's EVP & Chief Financial Officer, Scott Thomas Smith, has filed an amended Form 3 detailing his equity holdings in the company. The filing indicates he directly owns 4,017 Ordinary Shares, along with Restricted Stock Units (RSUs) covering 9,552, 3,197, and 4,24

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 20:10
Source
Stock Titan
Simply Wall Street Direct company coverage

Ascendis Pharma (Nasdaq:ASND) - Stock Analysis

Ascendis Pharma (ASND) is analyzed as undervalued by 12.1% with earnings forecasted to grow by 16.93% annually. The company recently became profitable and analysts expect a 33.3% rise in stock price. Recent news includes FDA approval for YUVIWEL, strong commercial traction for ot

Tone
Positive 74/100
Event
Earnings
Published
30 May 2026 20:09
Source
Simply Wall Street
Stock Titan Direct company coverage

Ascendis Pharma (ASND) director Bienaimé buys 400 Ordinary Shares

Ascendis Pharma A/S director Jean Jacques Bienaimé recently purchased 400 Ordinary Shares of the company in two open-market transactions on May 26, 2026. The shares were bought at weighted average prices of $236.235 and $239.3675 per share, totaling approximately $95,121. This in

Tone
Positive 72/100
Event
Market update
Published
27 May 2026 19:40
Source
Stock Titan